Review article: The treatment of functional abdominal bloating and distension

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 10, 2011, Pages 1071-1086

  Schmulson, M ^a   Chang, L ^b  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIARRHEAL AGENT; ANTIFOAMING AGENT; BULKING AGENT; COLCHICINE; DOPAMINE RECEPTOR BLOCKING AGENT; ISPAGULA; LAXATIVE; LINACLOTIDE; LUBIPROSTONE; MACROLIDE; MELATONIN; MUSCARINIC RECEPTOR BLOCKING AGENT; OPIATE; OTILONIUM BROMIDE; PEPPERMINT OIL; PLACEBO; POLYCARBOPHIL CALCIUM; PREBIOTIC AGENT; PROBIOTIC AGENT; PROKINETIC AGENT; RIFAXIMIN; SEROTONIN 1 AGONIST; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; SEROTONIN UPTAKE INHIBITOR; SPASMOLYTIC AGENT; SURFACTANT; TEGASEROD; TRIMEBUTINE; UNINDEXED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM LONGUM INFANTIS; BLOATING; CONSTIPATION; DIARRHEA; DIET THERAPY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ENTERITIS; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRACT FUNCTION; HERBAL MEDICINE; HUMAN; IMMUNOMODULATION; IRRITABLE COLON; LACTOBACILLUS; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; STOMACH DISTENSION; SYSTEMATIC REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ABDOMEN; DILATATION, PATHOLOGIC; FLATULENCE; GASES; GASTRIC DILATATION; GASTROINTESTINAL AGENTS; GASTROINTESTINAL TRANSIT; HUMANS; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79954897815     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04637.x     Document Type: Review

References (158)

1. Heaton KW, O'Donnell LJ, Braddon FE, Mountford RA, Hughes AO, Cripps PJ,. Symptoms of irritable bowel syndrome in a British urban community: consulters and nonconsulters. Gastroenterology 1992; 102: 1962-7.
2. Sandler RS, Stewart WF, Liberman JN, Ricci JA, Zorich NL,. Abdominal pain, bloating, and diarrhea in the United States: prevalence and impact. Dig Dis Sci 2000; 45: 1166-71. (Pubitemid 30409462)
3. Talley NJ, Boyce P, Jones M,. Identification of distinct upper and lower gastrointestinal symptom groupings in an urban population. Gut 1998; 42: 690-5. (Pubitemid 28261058)
4. Zar S, Benson MJ, Kumar D,. Review article: bloating in functional bowel disorders. Aliment Pharmacol Ther 2002; 16: 1867-76. (Pubitemid 35253002)
5. Azpiroz F, Malagelada JR,. Abdominal bloating. Gastroenterology 2005; 129: 1060-78. (Pubitemid 41242696)
6. Jiang X, Locke GR 3rd, Choung RS, Zinsmeister AR, Schleck CD, Talley NJ,. Prevalence and risk factors for abdominal bloating and visible distention: a population-based study. Gut 2008; 57: 756-63. (Pubitemid 351716967)
7. Chang L, Lee OY, Naliboff B, Schmulson M, Mayer EA,. Sensation of bloating and visible abdominal distension in patients with irritable bowel syndrome. Am J Gastroenterol 2001; 96: 3341-7. (Pubitemid 34016658)
8. Tuteja AK, Talley NJ, Joos SK, Tolman KG, Hickam DH,. Abdominal bloating in employed adults: prevalence, risk factors, and association with other bowel disorders. Am J Gastroenterol 2008; 103: 1241-8. (Pubitemid 351677968)
9. Thompson WG, the working team for Functional Gastrointestinal Disorders. Functional bowel disorders and functional abdominal pain. In:, Drossman DA, Richter JE, Talley NJ, Thompson WG, Corazziari E, Whitehead WE, eds. The Functional Gastrointestinal Disorders, 1st ed. Boston/New York/Toronto/London: Little, Brown and Co, 1994; 115-73.
10. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999; 45 (Suppl. 2): II43-7. (Pubitemid 29434812)
11. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC,. Functional bowel disorders. In:, Drossman DA, Corazziari E, Delvaux M, Spiller RC, Talley NJ, Thompson WG, Whitehead WE, eds. Rome III: The Functional Gastrointestinal Disorders, 3rd ed. Lawrence, KS: Allen Press, Inc., 2006; 487-556.
12. Drossman DA, Li Z, Andruzzi E, et al. US householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993; 38: 1569-80. (Pubitemid 23271409)
13. Jones M,. Bloating and intestinal gas. Curr Treat Options Gastroenterol 2005; 8: 311-8. (Pubitemid 41223403)
14. Serra J, Azpiroz F, Malagelada JR,. Mechanisms of intestinal gas retention in humans: impaired propulsion versus obstructed evacuation. Am J Physiol Gastrointest Liver Physiol 2001; 281: G138-43.
15. Serra J, Azpiroz F, Malagelada JR,. Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. Gut 2001; 48: 14-9. (Pubitemid 32042636)
16. Hernando-Harder AC, Serra J, Azpiroz F, et al. Colonic responses to gas loads in subgroups of patients with abdominal bloating. Am J Gastroenterol 2010; 10: 876-82.
17. Song JY, Merskey H, Sullivan S, Noh S,. Anxiety and depression in patients with abdominal bloating. Can J Psychiatry 1993; 38: 475-9. (Pubitemid 23337848)
18. Sullivan SN,. Functional abdominal bloating. J Clin Gastroenterol 1994; 19: 23-7. (Pubitemid 24222235)
19. Haderstorfer B, Psycholgin D, Whitehead WE, Schuster MM,. Intestinal gas production from bacterial fermentation of undigested carbohydrate in irritable bowel syndrome. Am J Gastroenterol 1989; 84: 375-8. (Pubitemid 19106398)
20. Maxton DG, Martin DF, Whorwell PJ, Godfrey M,. Abdominal distension in female patients with irritable bowel syndrome: exploration of possible mechanisms. Gut 1991; 32: 662-4.
21. Accarino A, Perez F, Azpiroz F, Quiroga S, Malagelada JR,. Abdominal distention results from caudo-ventral redistribution of contents. Gastroenterology 2009; 136: 1544-51.
22. Houghton LA, Whorwell PJ,. Towards a better understanding of abdominal bloating and distension in functional gastrointestinal disorders. Neurogastroenterol Motil 2005; 17: 500-11. (Pubitemid 41075991)
23. Lin HC,. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 2004; 292: 852-8. (Pubitemid 39079672)
24. Baldi F, Longanesi A, Blasi A, et al. Octylonium bromide in the treatment of the irritable bowel syndrome: a clinical-functional study. Hepatogastroenterology 1992; 39: 392-5.
25. Fidelholtz J, Smith W, Rawls J, et al. Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms. Am J Gastroenterol 2002; 97: 1176-81. (Pubitemid 34478118)
26. Mangel AW, Chaturvedi P,. Evaluation of Crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients. Digestion 2008; 78: 180-6.
27. Corazza GR, Biagi F, Albano O, et al. Levosulpiride in functional dyspepsia: a multicentric, double-blind, controlled trial. Ital J Gastroenterol 1996; 28: 317-23. (Pubitemid 26320804)
28. Piai G, Mazzacca G,. Prifinium bromide in the treatment of the irritable colon syndrome. Gastroenterology 1979; 77: 500-2. (Pubitemid 9220414)
29. Lembo AJ, Cremonini F, Meyers N, Hickling R,. Clinical trial: renzapride treatment of women with irritable bowel syndrome and constipation-a double-blind, randomized, placebo-controlled, study. Aliment Pharmacol Ther 2010; 31: 979-90.
30. Lembo AJ, Kurtz CB, Macdougall JE, et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology 2010; 138: 886-95.
31. Tack J, Broekaert D, Fischler B, Van Oudenhove L, Gevers AM, Janssens J,. Acontrolled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006; 55: 1095-103. (Pubitemid 44085674)
32. Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome-results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009; 29: 329-41.
33. Shepherd SJ, Parker FC, Muir JG, Gibson PR,. Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence. Clin Gastroenterol Hepatol 2008; 6: 765-71.
34. Tack OB,. Otilonium bromide improves and delays time to post-treatment relapse in irritable bowel syndrome. Gastroenterology 2010; 138 (Suppl. 1): S223.
35. Lembo A, Schneider H, Lavins BJ, et al. Efficacy and safety of once daily linaclotide administered orally for 12 weeks in patients with chronic constipation: results from 2 randomized, double blind, placebo-controlled phase 3 trials. Gastroenterology 2010; 138 (Suppl. 1): S53-4.
36. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364: 22-32.
37. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12. (Pubitemid 26120810)
38. Robayo-Torres CC, Quezada-Calvillo R, Nichols BL,. Disaccharide digestion: clinical and molecular aspects. Clin Gastroenterol Hepatol 2006; 4: 276-87. (Pubitemid 43343881)
39. Bernstein JE, Kasich AM,. A double-blind trial of simethicone in functional disease of the upper gastrointestinal tract. J Clin Pharmacol 1974; 14: 617-23.
40. Lecuyer M, Cousin T, Monnot MN, Coffin B,. Efficacy of an activated charcoal-simethicone combination in dyspeptic syndrome: results of a randomized prospective study in general practice. Gastroenterol Clin Biol 2009; 33: 478-84.
41. Ford AC, Talley NJ, Spiegel BM, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008; 337: A2313.
42. Quigley E, Fried M, Gwee KA, et al. Irritable Bowel Syndrome: A Global Perspective. World Gastroenterology Organization Global Guidelines. Available at:.
43. Delvaux M, Wingate D,. Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results. J Int Med Res 1997; 25: 225-46. (Pubitemid 27472752)
44. Lüttecke K,. A three-part controlled study of trimebutine in the treatment of irritable colon syndrome. Curr Med Res Opin 1980; 6: 437-43. (Pubitemid 10111293)
45. Darvish-Damavandi M, Nikfar S, Abdollahi M,. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol 2010; 16: 547-53.
46. DumitraÅcu DL, StÄnculete M,. The effect of trimebutine on the psychosocial adjustment to illness in the irritable bowel syndrome. Rom J Intern Med 2006; 44: 273-80.
47. Maggi CA, Manzini S, Meli A,. Octylonium bromide: a smooth muscle relaxant which interferes with calcium ions mobilization. Arch Int Pharmacodyn Ther 1983; 264: 305-23. (Pubitemid 13050103)
48. Baldi F, Longanesi A, Blasi A, et al. Clinical and functional evaluation of the efficacy of otilonium bromide: a multicenter study in Italy. Ital J Gastroenterol 1991; 23 (Suppl. 1): 60-3.
49. Battaglia G, Morselli-Labate AM, Camarri E, et al. Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled, 15-week study. Aliment Pharmacol Ther 1998; 12: 1003-10. (Pubitemid 28454384)
50. Glende M, Morselli-Labate AM, Battaglia G, Evangelista S,. Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome. Eur J Gastroenterol Hepatol 2002; 14: 1331-8. (Pubitemid 36054922)
51. Villagrasa M, Boix J, Humbert P, Quer JC,. Aleatory clinical study comparing otilonium bromide with a fiber-rich diet in the treatment of irritable bowel syndrome. Ital J Gastroenterol 1991; 23 (Suppl. 1): 67-70.
52. Liu JH, Chen GH, Yeh HZ, Huang CK, Poon SK,. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol 1997; 32: 765-8.
53. Cappello G, Spezzaferro M, Grossi L, Manzoli L, Marzio L,. Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: aprospective double blind placebo-controlled randomized trial. Dig Liver Dis 2007; 39: 530-6. (Pubitemid 46746646)
54. Prior A, Whorwell PJ,. Double blind study of ispaghula in irritable bowel syndrome. Gut 1987; 28: 1510-3. (Pubitemid 17164088)
55. Toskes PP, Connery KL, Ritchey TW,. Calcium polycarbophil compared with placebo in irritable bowel syndrome. Aliment Pharmacol Ther 1993; 7: 87-92. (Pubitemid 23053393)
56. DiPalma JA, DeRidder PH, Orlando RC, Kolts BE, Cleveland MB,. A randomized, placebo-controlled, multicenter study of the safety and efficacy of a new polyethylene glycol laxative. Am J Gastroenterol 2000; 95: 446-50. (Pubitemid 30106174)
57. DiPalma JA, Cleveland MB, McGowan J, Herrera JL,. A comparison of polyethylene glycol laxative and placebo for relief of constipation from constipating medications. South Med J 2007; 100: 1085-90. (Pubitemid 350071173)
58. Cuppoletti J, Malinowska DH, Tewari KP, et al. SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol 2004; 287: C1173-83. (Pubitemid 39382875)
59. Camilleri M, Bharucha AE, Ueno R, et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2006; 290: G942-7.
60. Sweetser S, Busciglio IA, Camilleri M, et al. Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. Am J Physiol Gastrointest Liver Physiol 2009; 296: G295-301.
61. Johanson JF, Morton D, Geenen J, Ueno R,. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 2008; 1031: 170-7.
62. Andresen V, Camilleri M, Busciglio IA, et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation- predominant irritable bowel syndrome. Gastroenterology 2007; 133: 761-8. (Pubitemid 47374145)
63. Sanger GJ,. Translating 5-HT receptor pharmacology. Neurogastroenterol Motil 2009; 21: 1235-8.
64. Tonini M, Cipollina L, Poluzzi E, Crema F, Corazza GR, De Ponti F,. Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther 2004; 19: 379-90. (Pubitemid 38297106)
65. Johnson AG,. Controlled trial of metoclopramide in the treatment of flatulent dyspepsia. Br Med J 1971; 2: 25-6.
66. Mearin F, Rodrigo L, Pérez-Mota A, et al. Levosulpiride and cisapride in the treatment of dysmotility-like functional dyspepsia: a randomized, double-masked trial. Clin Gastroenterol Hepatol 2004; 2: 301-8. (Pubitemid 38447194)
67. Milo R,. Use of the peripheral dopamine antagonist, domperidone, in the management of gastro-intestinal symptoms in patients with irritable bowel syndrome. Curr Med Res Opin 1980; 6: 577-84. (Pubitemid 11237312)
68. Cann PA, Read NW, Holdsworth CD,. Oral domperidone: double blind comparison with placebo in irritable bowel syndrome. Gut 1983; 24: 1135-40. (Pubitemid 14205815)
69. Doi Y, Murasaki O, Kaibara M, et al. Characterization of functional effects of Z-338, a novel gastroprokinetic agent, on the muscarinic M1, M2, and M3 receptors expressed in Xenopus oocytes. Eur J Pharmacol 2004; 505: 31-5. (Pubitemid 39535673)
70. Tack J, Masclee A, Heading R, et al. A dose-ranging, placebo-controlled, pilot trial of Acotiamide in patients with functional dyspepsia. Neurogastroenterol Motil 2009; 21: 272-80.
71. Champion MC, MacCannell KL, Thomson AB, et al. A double-blind randomized study of cisapride in the treatment of nonulcer dyspepsia. The Canadian Cisapride Nud Study Group. Can J Gastroenterol 1997; 11: 127-34. (Pubitemid 27146011)
72. Kellow JE, Cowan H, Shuter B, et al. Efficacy of cisapride therapy in functional dyspepsia. Aliment Pharmacol Ther 1995; 9: 153-60.
73. Chung JM,. Cisapride in chronic dyspepsia: results of a double-blind, placebo-controlled trial. Scand J Gastroenterol Suppl 1993; 195: 11-4. (Pubitemid 23135137)
74. Al-Quorain A, Larbi EB, al-Shedoki F,. A double-blind, randomized, placebo-controlled trial of cisapride in Saudi Arabs with functional dyspepsia. Scand J Gastroenterol 1995; 30: 531-4.
75. Chen JD, Ke MY, Lin XM, Wang Z, Zhang M,. Cisapride provides symptomatic relief in functional dyspepsia associated with gastric myoelectrical abnormality. Aliment Pharmacol Ther 2000; 14: 1041-7. (Pubitemid 30618165)
76. Farup PG, Hovdenak N, Wetterhus S, Lange OJ, Hovde O, Trondstad R,. The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation. Scand J Gastroenterol 1998; 33: 128-31. (Pubitemid 28098225)
77. Schütze K, Brandstätter G, Dragosics B, Judmaier G, Hentschel E,. Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11: 387-94. (Pubitemid 27183521)
78. Van Outryve M, Milo R, Toussaint J, Van Eeghem P,. "Prokinetic" treatment of constipation-predominant irritable bowel syndrome: a placebo-controlled study of cisapride. J Clin Gastroenterol 1991; 13: 49-57.
79. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G,. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000; 118: 463-8. (Pubitemid 30140843)
80. Vakil N, Laine L, Talley NJ, et al. Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials. Am J Gastroenterol 2008; 103: 1906-19.
81. Müller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001; 15: 1655-66. (Pubitemid 32912410)
82. Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002; 16: 1877-88.
83. Kellow J, Lee OY, Chang FY, et al. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003; 52: 671-6. (Pubitemid 36528868)
84. Tack J, Müller-Lissner S, Bytzer P, et al. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut 2005; 54: 1707-13. (Pubitemid 41697668)
85. Johanson JF, Wald A, Tougas G, et al. Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial. Clin Gastroenterol Hepatol 2004; 2: 796-805. (Pubitemid 39200718)
86. Kamm MA, Müller-Lissner S, Talley NJ, et al. Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study. Am J Gastroenterol 2005; 100: 362-72. (Pubitemid 40314521)
87. On Chan AO, Mo Hui W, Leung G, Hu WH, Lam SK, Wong BC,. Efficacy of tegaserod for functional constipation in Chinese subjects: a randomized double-blind controlled trial in a single centre. Aliment Pharmacol Ther 2007; 25: 463-9. (Pubitemid 46184460)
88. Brandt LJ,. The FDA's decision-making process: isn't it time to temper the principle of protective paternalism? Am J Gastroenterol 2008; 103: 1226-7. (Pubitemid 351677996)
89. Thompson CA,. Novartis suspends tegaserod sales at FDA's request. Am J Health Syst Pharm 2007; 64: 1020. (Pubitemid 46801527)
90. Arts J, Caenepeel P, Verbeke K, Tack J,. Influence of erythromycin on gastric emptying and meal related symptoms in functional dyspepsia with delayed gastric emptying. Gut 2005; 54: 455-60. (Pubitemid 40395493)
91. Verne GN, Eaker EY, Davis RH, Sninsky CA,. Colchicine is an effective treatment for patients with chronic constipation: an open-label trial. Dig Dis Sci 1997; 42: 1959-63. (Pubitemid 27433547)
92. Bueno L, de Ponti F, Fried M, et al. Serotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity. Neurogastroenterol Motil 2007; 19 (Suppl. 1): 89-119. (Pubitemid 46058984)
93. Gershon M, Tack J,. The serotonin signalling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007; 132: 397-414. (Pubitemid 46127672)
94. Malatesta MG, Fascetti E, Ciccaglione AF, et al. 5-HT1-receptor agonist sumatriptan modifies gastric size after 500 ml of water in dyspeptic patients and normal subjects. Dig Dis Sci 2002; 47: 2591-5. (Pubitemid 35305471)
95. Tack J, Van Den Elzen B, Tytgat G, et al. A placebo-controlled trial of the 5-HT1A agonist R-137696 on symptoms, visceral hypersensitivity and on impaired accommodation in functional dyspepsia. Neurogastroenterol Motil 2009; 21: 619-26.
96. Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, Moayyedi P,. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2009; 104: 1831-43.
97. Maxton DG, Morris J, Whorwell PJ,. Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia? Aliment Pharmacol Ther 1996; 10: 595-9. (Pubitemid 26254803)
98. Camilleri M, Chey WY, Mayer EA, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001; 161: 1733-40. (Pubitemid 32679548)
99. Chey WD, Chey WY, Heath AT, et al. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2004; 99: 2195-203. (Pubitemid 39524711)
100. Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA,. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol 2005; 100: 115-23. (Pubitemid 41623278)
101. Schmulson M, Lee OY, Chang L, Naliboff B, Mayer EA,. Symptom differences in moderate to severe IBS patients based on predominant bowel habit. Am J Gastroenterol 1999; 94: 2929-35. (Pubitemid 29482760)
102. Kuiken SD, Tytgat GN, Boeckxstaens GE,. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol 2003; 1: 219-28. (Pubitemid 37248073)
103. Vahedi H, Merat S, Rashidioon A, Ghoddoosi A, Malekzadeh R,. The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study. Aliment Pharmacol Ther 2005; 22: 381-5. (Pubitemid 41248104)
104. Tabas G, Beaves M, Wang J, Friday P, Mardini H, Arnold G,. Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol 2004; 99: 914-20. (Pubitemid 39090223)
105. Corazziari E,. Role of opioid ligands in the irritable bowel syndrome. Can J Gastroenterol 1999; 13 (Suppl. A): 71A-5A.
106. De Luca A, Coupar IM,. Insights into opioid action in the intestinal tract. Pharmacol Ther 1996; 69: 103-15. (Pubitemid 26111425)
107. Foxx-Orenstein AE, Jin JG, Grider JR,. 5-HT4 receptor agonists and delta-opioid receptor antagonists act synergistically to stimulate colonic propulsion. Am J Physiol 1998; 275 (5 Pt 1): G979-83.
108. Fraitag B, Homerin M, Hecketsweiler P,. Double-blind dose-response multicenter comparison of fedotozine and placebo in treatment of nonulcer dyspepsia. Dig Dis Sci 1994; 39: 1072-7. (Pubitemid 24188852)
109. Dapoigny M, Abitbol JL, Fraitag B,. Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study. Dig Dis Sci 1995; 40: 2244-9.
110. Hawkes ND, Rhodes J, Evans BK, Rhodes P, Hawthorne AB, Thomas GA,. Naloxone treatment for irritable bowel syndrome-a randomized controlled trial with an oral formulation. Aliment Pharmacol Ther 2002; 16: 1649-54.
111. Doherty NS, Hancock AA,. Role of alpha-2 adrenergic receptors in the control of diarrhea and intestinal motility. J Pharmacol Exp Ther 1983; 225: 269-74. (Pubitemid 13091212)
112. Prior A, Wilson KM, Whorwell PJ,. Double-blind study of an alpha 2 agonist in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1988; 2: 535-9.
113. Dumitrascu DL, Stanculete M, Mitrea I, Dumitrascu DM, Farcas A,. The effect of two antidiarrhoeal drugs on the psychosocial adjustment to illness in chronic functional diarrhoea. Rom J Intern Med 2004; 42: 191-7.
114. Fumi AL, Trexler K,. Rifaximin treatment for symptoms of irritable bowel syndrome. Ann Pharmacother 2008; 42: 408-12. (Pubitemid 351429607)
115. Di Stefano M, Strocchi A, Malservisi S, Veneto G, Ferrieri A, Corazza GR,. Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms. Aliment Pharmacol Ther 2000; 14: 1001-8. (Pubitemid 30618160)
116. Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I,. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006; 101: 326-33. (Pubitemid 43381675)
117. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y,. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006; 17: 145.
118. O'Sullivan MA, O'Morain CA,. Bacterial supplementation in the irritable bowel syndrome. A randomized double-blind placebo-controlled crossover study. Dig Liver Dis 2000; 32: 294-301. (Pubitemid 30445067)
119. King TS, Elia M, Hunter JO,. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998; 352: 1187-9. (Pubitemid 28458534)
120. Treem WR, Shoup ME, Hale DE, et al. Acute fatty liver of pregnancy, hemolysis, elevated liver enzymes, and low platelets syndrome, and long chain 3-hydroxyacyl-coenzyme Adehydrogenase deficiency. Am J Gastroenterol 1996; 91: 2293-300. (Pubitemid 26383188)
121. FAO/WHO (2002). Guidelines for the Evaluation of Probiotics in Food. Joint working group report on drafting guidelines for the evaluation of probiotics in food. Available at:.
122. Schrezenmeir J, de Vrese M,. Probiotics, prebiotics, and synbiotics-approaching a definition. Am J Clin Nutr 2001; 73 (Suppl. 2): 361S-4S. (Pubitemid 32113256)
123. Gibson GR, Roberfroid MB,. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 1995; 125: 1401-12.
124. Nobaek S, Johansson ML, Molin G, Ahrné S, Jeppsson B,. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000; 95: 1231-8. (Pubitemid 30263518)
125. Niv E, Naftali T, Hallak R, Vaisman N,. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome-a double blind, placebo-controlled, randomized study. Clin Nutr 2005; 24: 925-31. (Pubitemid 41782449)
126. Kim LS, Hilli L, Orlowski J, Kupperman JL, Baral M, F Waters R,. Efficacy of probiotics and nutrients in functional gastrointestinal disorders: a preliminary clinical trial. Dig Dis Sci 2006; 51: 2134-44.
127. Hun L,. Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. Postgrad Med 2009; 121: 119-24.
128. Koebnick C, Wagner I, Leitzmann P, Stern U, Zunft HJ,. Probiotic beverage containing Lactobacillus casei Shirota improves gastrointestinal symptoms in patients with chronic constipation. Can J Gastroenterol 2003; 17: 655-9. (Pubitemid 37536846)
129. Kalman DS, Schwartz HI, Alvarez P, Feldman S, Pezzullo JC, Krieger DR,. A prospective, randomized, double-blind, placebo-controlled parallel-group dual site trial to evaluate the effects of a Bacillus coagulans-based product on functional intestinal gas symptoms. BMC Gastroenterol 2009; 9: 85.
130. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006; 101: 1581-90. (Pubitemid 43980633)
131. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541-51. (Pubitemid 40585355)
132. Pochart P, Marteau P, Bouhnik Y, Goderel I, Bourlioux P, Rambaud JC,. Survival of Bifidobacteria ingested via fermented milk during their passage through the human small intestine: an in vivo study using intestinal perfusion. Am J Clin Nutr 1992; 55: 78-80.
133. Guyonnet D, Chassany O, Ducrotte P, et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind,controlled trial. Aliment Pharmacol Ther 2007; 26: 475-86. (Pubitemid 47063138)
134. Guyonnet D, Schlumberger A, Mhamdi L, Jakob S, Chassany O,. Fermented milk containing Bifidobacterium lactis DN-173 010 improves gastrointestinal well-being and digestive symptoms in women reporting minordigestive symptoms: a randomised, double-blind, parallel, controlled study. Br J Nutr 2009; 102: 1654-62.
135. Kajander K, Hatakka K, Poussa T, Färkkilä M, Korpela R,. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 2005; 22: 387-94. (Pubitemid 41248105)
136. Huang JS, Bousvaros A, Lee JW, Diaz A, Davidson EJ,. Efficacy of probiotic use in acute diarrhea in children: a meta-analysis. Dig Dis Sci 2002; 47: 2625-34. (Pubitemid 35305477)
137. Ouwehand AC, Lagström H, Suomalainen T, Salminen S,. Effect of probiotics on constipation, fecal azoreductase activity and fecal mucin content in the elderly. Ann Nutr Metab 2002; 46: 159-62. (Pubitemid 34920700)
138. Kim HJ, Camilleri M, McKinzie S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17: 895-904. (Pubitemid 36459602)
139. Kim HJ, Vazquez Roque MI, Camilleri M, et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005; 17: 687-96. (Pubitemid 41400717)
140. Olesen M, Gudmand-Hoyer E,. Efficacy, safety, and tolerability of fructooligosaccharides in the treatment of irritable bowel syndrome. Am J Clin Nutr 2000; 72: 1570-5.
141. Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR,. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther 2009; 29: 508-18.
142. Tsuchiya J, Barreto R, Okura R, Kawakita S, Fesce E, Marotta F,. Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin J Dig Dis 2004; 5: 169-74. (Pubitemid 40028569)
143. Vejdani R, Shalmani HR, Mir-Fattahi M, et al. The efficacy of an herbal medicine, Carmint, on the relief of abdominal pain and bloating in patients with irritable bowel syndrome: a pilot study. Dig Dis Sci 2006; 51: 1501-7. (Pubitemid 44315821)
144. Saito YA, Rey E, Almazar-Elder AE, et al. A randomized, double-blind, placebo-controlled trial of St John's Word for treating irritable bowel syndrome. Am J Gastroenterol 2010; 105: 170-7.
145. Sallon S, Ben-Arye E, Davidson R, Shapiro H, Ginsberg G, Ligumsky M,. A novel treatment for constipation-predominant irritable bowel syndrome using Padma Lax, a Tibetan herbal formula. Digestion 2002; 65: 161-71. (Pubitemid 34914035)
146. Anastasi JK, McMahon DJ, Kim GH,. Symptom management for irritable bowel syndrome: a pilot randomized controlled trial of acupuncture/moxibustion. Gastroenterol Nurs 2009; 32: 243-55.
147. Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001; 134: 663-94. (Pubitemid 32322245)
148. MacPherson H, White A, Cummings M, et al. Standards for reporting interventions in controlled trials of acupuncture: the STRICTA recommendations. J Altern Complement Med 2002; 8: 85-9. (Pubitemid 34174391)
149. Kunz D, Mahlberg R, Müller C, Tilmann A, Bes F,. Melatonin in patients with reduced REM sleep duration: two randomized controlled trials. J Clin Endocrinol Metab 2004; 89: 128-34. (Pubitemid 38183871)
150. Bubenik GA,. Thirty four years since the discovery of gastrointestinal melatonin. J Physiol Pharmacol 2008; 59 (Suppl. 2): 33-51.
151. Thor PJ, Krolczyk G, Gil K, Zurowski D, Nowak L,. Melatonin and serotonin effects on gastrointestinal motility. J Physiol Pharmacol 2007; 58 (Suppl. 6): 97-103.
152. Song GH, Leng PH, Gwee KA, Moochhala SM, Ho KY,. Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study. Gut 2005; 54: 1402-7. (Pubitemid 41375196)
153. Whorwell PJ, Prior A, Faragher EB,. Controlled trial of hypnotherapy in the treatment of severe refractory irritable-bowel syndrome. Lancet 1984; 2: 1232-4. (Pubitemid 15217715)
154. Schmulson M, Adeyemo M, Gutiérrez-Reyes G, et al. Differences in gastrointestinal symptoms according to gender in Rome II positive IBS and dyspepsia in a Latin American population. Am J Gastroenterol 2010; 105: 925-32.
155. Adeyemo MA, Spiegel BM, Chang L,. Meta-analysis: do irritable bowel syndrome symptoms vary between men and women? Aliment Pharmacol Ther 2010; 32: 738-55.
156. Heitkemper MM, Chang L,. Do fluctuations in ovarian hormones affect gastrointestinal symptoms in women with irritable bowel syndrome? Gend Med 2009; 6 (Suppl. 2): 152-67.
157. Mathias JR, Clench MH, Reeves-Darby VG, et al. Effect of leuprolide acetate in patients with moderate to severe functional bowel disease. Double-blind, placebo-controlled study. Dig Dis Sci 1994; 39: 1155-62. (Pubitemid 24190250)
158. Mathias JR, Clench MH, Abell TL, et al. Effect of leuprolide acetate in treatment of abdominal pain and nausea in premenopausal women with functional bowel disease: a double-blind, placebo-controlled, randomized study. Dig Dis Sci 1998; 43: 1347-55. (Pubitemid 28272574)